Preclinical studies have shown a significant increase in phagocytosis in AML cell lines treated with the combination of magrolimab plus azacitidine and venetoclax compared to magrolimab and azacitidine plus venetoclax alone, including venetoclax-resistant and TP53-mutant cell lines [76]. This evidence concerns the gene TP53 and acute myeloid leukemia.